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The evaluation of plasma arginine, arginase, and nitric oxide
levels in patients with esophageal cancer
İbrahim KAPLAN1, Yener AYDIN2, Yusuf BİLEN3, Fatma GENÇ4, Mevlüt Sait KELEŞ1, Atila EROĞLU2

Aim: Many studies have been conducted to investigate plasma arginine, arginase, and nitric oxide (NO) levels in patients
with different types of cancer, and it has been suggested that these might be important factors for patients with cancer.
In the present study, plasma arginine, arginase, and nitric oxide levels were evaluated in patients with esophageal cancer.
Materials and methods: A total of 100 patients (51 females and 49 males) diagnosed with esophageal cancer but not yet
operated on were included in the study. The mean age of the study population was 62.03 ± 12.4 years. Patients treated
with radiotherapy or chemotherapy were excluded. The control group included 80 subjects (38 females and 42 males)
with a mean age of 57 ± 12.4 years. Plasma arginine, NO levels, and arginase activity were measured. High-performance
liquid chromatography, Griess reactions, and modified Geyer and Dabich methods were used to detect the arginine
levels, NO levels, and arginase activity.
Results: In patients with esophageal cancer, plasma arginine concentrations were significantly lower and NO levels
and arginase activity were significantly higher than in the control groups (P < 0.0001, P < 0.0001, and P = 0.005,
respectively). The sensitivity of arginase and NO were estimated at 87% and 89%, with respective specificities of 65% and
66%. Between the patients with and without distant organ metastasis, there were no significant differences in arginine/
NO levels and arginase activity (P > 0.05). Similarly, there were no significant differences in these parameters between
the patients with squamous cell carcinoma and adenocarcinoma (P > 0.05).
Conclusion: The results demonstrate that plasma NO levels and arginase activity may be used as markers for the
diagnosis of esophageal cancer. However, larger and more comprehensive studies are needed.
Key words: Esophageal cancer, arginase, arginine, nitric oxide

Özofagus kanserli olgularda plazma arginin, arginaz ve nitrik oksit seviyelerinin
değerlendirilmesi
Amaç: Çeşitli kanserlerde plazma arginin, arginaz ve nitrik oksit (NO) ile ilgili birçok çalışma yapılmış ve bu
parametrelerin kanser hastaları için belirleyici faktörler olabileceği ileri sürülmüştür. Bu çalışmada özofagus kanserli
hastalarda plazma arjinin, arjinaz ve nitrik oksit seviyeleri değerlendirildi.
Yöntem ve gereç: Çalışmaya özofagus kanseri tanısı konup henüz opere edilmemiş 51’i kadın ve 49’u erkek olmak üzere
100 hasta dahil edildi. Olguların yaş ortalamaları 62,03 ± 12,4 idi. Radyoterapi veya kemoterapi alan hastalar çalışmaya
dahil edilmedi. Yaş ortalamaları 57 ± 12,4 olan 38 kadın ve 42 erkek olmak üzere 80 bireyden oluşan kontrol grubu
oluşturuldu. Olguların plazma arginin ve NO düzeyi ile arginaz aktivitesi ölçüldü. Arginin düzeyi yüksek performanslı
likit kromatografi yöntemi, nitrik oksit düzeyi Griess reaksiyonuyla, arginaz aktivitesi ise modifiye Geyer ve Dabich
metoduyla ölçüldü.
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Bulgular: Plazma arginin konsantrasyonu özofagus kanserli hastalarda kontrol grubuna oranla belirgin derecede
düşük, nitrik oksit düzeyi ve arginaz aktivitesi ise kontrol grubuna oranla önemli derecede yüksek bulundu (sırasıyla P
< 0,0001, P < 0,0001 ve P = 0,005). Arginaz ve nitrik oksitin sensitivitesi % 87 ve % 89, spesifitesi ise % 65 ve % 66 olarak
hesaplandı. Arginin, nitrik oksit düzeyleri ve arginaz aktivitesi, uzak organ metastazı olan hastalar ile metastaz olmayan
hastalarla kıyaslandığında istatistiksel olarak anlamlı bir fark bulunmadı (P > 0,05). Benzer şekilde bu parametreler yassı
epitel hücreli karsinom ve adenokarsinomalı hastalar ile kıyaslandığında da istatiksel olarak anlamlı bir fark saptanmadı
(P > 0,05).
Sonuç: Elde ettiğimiz sonuçlar özofagus kanserli hastaların tanısında plazma NO düzeyi ile arginaz aktivitesinin
bir tümör belirteci olarak kullanılabileceğini göstermektedir. Ancak bununla ilgili daha kapsamlı ve ileri düzeyde
çalışmalara ihtiyaç vardır.
Anahtar sözcükler: Özofagus kanseri, arginaz, arginin, nitrik oksit

Introduction

Materials and methods

Nitric oxide is one of the free oxygen radicals
produced by nitric oxide synthase (NOS) activity
from arginine and it has double-sided effects. NO
is necessary for many physiological functions and it
contributes to antioxidant defense. In addition, it has
a radical effect in the event of overproduction and
causes more radical compounds such as peroxynitrite
(1).

Patient selection

Increased arginase activity may limit NOS activity
and lead to a weakening of the inhibitor effect on
xanthine oxidase activity. In this case, it results in
more superoxide radical production and tissue
damage (2).
Since arginine is the nitrogen donor in NO
synthesis, recently there has been an increased
interest in this amino acid. The biochemistry
of arginine, which is the precursor of NO and
polyamines, stimulating the secretion of endogenous
growth hormone with positive effects on wound
healing and immunological aspects, is complex and
involves many of the main metabolic pathways and
organ systems (3-5).
The present study aimed to evaluate plasma
arginine, arginase, and NO levels in patients with
esophageal cancer; to evaluate the differences
between patients with squamous cell carcinoma
and adenocarcinoma in terms of plasma arginine,
arginase, and NO levels; and to evaluate the
differences between patients with and without
distant organ metastasis in terms of plasma arginine,
arginase, and NO levels.
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In the present study, 100 patients (51 females and 49
males) diagnosed with esophageal cancer but not yet
operated on at the Ataturk University Medical Faculty
Research Hospital’s Thorax Surgery Department
in 2008 and 2009 were included. Patients treated
with radiotherapy or chemotherapy were excluded.
Patients with systemic chronic diseases such as
diabetes or hypertension were not included. Patients
using any drugs were excluded.
The mean age of the patients was 62.03 ± 12.4 years.
The control group included 80 healthy subjects with
38 females and 42 males. The mean age of the control
group was 57 ± 12.4 years.
Collection of blood samples
Venous blood samples were taken from the
patient and control groups into tubes containing
ethylenediaminetetraacetic acid (EDTA). The tubes
were placed in a cooled centrifuge at 2000 rpm for 10
min at 10-18 °C, and then the obtained plasma was
stored in Eppendorf tubes at –80 °C until analysis.
Thawing was permitted only once and the samples
were checked for significant hemolysis or lipemia. The
frozen samples were thawed at room temperature.
Arginase measurement
Plasma arginase activity was studied using the Geyer
and Dabich method with serum modifications (4,5).
In this method, arginase activity was determined
using L-arginine as a substrate, and then the amount
of urea from the arginase hydrolysis was determined
using the thiosemicarbazide-diacetylmonoximeurea (TDMU) method (6) spectrophotometrically at
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520 nm. Urea accumulation proportionally reflects
arginase activity.
NO measurement
In determining the concentration of nitrate
+ nitrite, nitrates are reduced to nitrites with
nitrate reductase enzyme and the total nitrite
concentration is measured. Nitrite measurements
are a spectrophotometric measurement based on
the Griess reaction (6). Phosphoric acid (H3PO4)
in the Griess reagent reacts with the nitrite and
nitrous acid occurs. The nitrous acid reacts with the
sulfanilamide and diazobenzenesulfonic acid occurs.
Reaction with naphthyl ethylenediamine causes the
dark pink-colored complex (an azo compound). The
color intensity of this compound is measured with a
spectrophotometer.
Arginine measurement
The plasma arginine level was determined using
the Agilent Hewlett Packard 1100 Modular System
and the high-performance liquid chromatography
(HPLC) method. First, 300 mL of plasma was
adjusted with 200 mL of SERAPREP solution to a
pH of 2.3. It was then centrifuged for 3 min at 10,000
rpm. The supernatant was measured by HPLC.
Statistical analysis
Statistical analysis of the data was performed using
SPSS 11.0. Results were expressed as means ±
standard deviations. First, the data were searched for
normal distribution. Data with normal distribution
were compared by independent t-tests. P < 0.05 was
considered significant. The relationship between
2 different parameters was assessed by Pearson’s
correlation tests.

Results
No significant difference was found between the
esophageal cancer patients and the control group
for age and sex (P > 0.05). Of the patients, 78%
of had squamous cell carcinoma and 22% had
adenocarcinoma. Tumors were located in the upper
third, middle third, and distal third of the esophagus
in 7%, 45%, and 48% of the patients, respectively.
Mean arginase activity was measured as 10.4 ± 9.3
U/L and 7.5 ± 4.8 U/L in the patients and the control
group, respectively. Arginase activity in the patient
group was significantly higher than in the control
group, with statistical significance (P = 0.005).
Mean NO levels were 16.2 ± 3.0 μmol/L and 10.1
± 1.2 μmol/L in the patients and the control group,
respectively. NO levels in the patient group were
significantly higher than in the control group (P =
0.0001).
Mean arginine levels were 41.9 ± 13.4 μmol/L and
83.8 ± 26.8 μmol/L in the patients and the control
group, respectively. Arginine levels in the patient
group were significantly lower than in the control
group (P = 0.0001).
Patients and controls were grouped according to
sex and analyzed separately. Arginase activity, NO
levels, and arginine levels were compared between
the sexes in the patient group and control group and
no statistically significant difference was found (P >
0.05) (Table 1).
Of the 100 patients in the study with esophageal
cancer, there were 15 distant metastases (7 patients
with liver metastasis, 6 patients with lung metastasis,
and 2 patients with bone metastasis). Mean arginase
activity in patients with and without metastases

Table 1. Sex distribution of the parameters in both groups.
Patients with esophageal cancer

Control group

P

Parameters
Male

Female

Male

Female

Arginase activity (U/L)

10.4 ± 8.2

10.7 ± 7.1

7.8 ± 4.3

7.2 ± 3.9

P > 0.05

NO level (μmol/L)

16.6 ± 4.3

15.8 ± 5.4

10.4 ± 1.9

9.8 ± 2.7

P > 0.05

Arginine level (μmol/L)

42.5 ± 11.9

41.4 ± 15.6

84.2 ± 22.4

81.8 ± 25.1

P > 0.05
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was 10.1 ± 9.4 U/L and 8.1 ± 7.0 U/L, respectively.
Arginase activity in patients with metastasis was
higher, but no statistical significance was determined
(P = 0.26).
While the mean NO levels in patients with distant
metastases was 10.1 ± 5.3 mmol/L, the mean NO
levels in patients without metastasis was 13.0 ± 4.1
mmol/L. NO levels in patients without metastasis
were higher, but this was not statistically significant
(P = 0.31).
The arginine levels in patients with and without
distant metastases were 40.3 ± 11.3 mmol/L and 43.6
± 25.7 mmol/L, respectively. Despite the high level of
arginine in patients without metastasis, the difference
was not statistically significant (P = 0.608).
Pearson’s correlation test was performed for
arginase activity, NO levels, and arginine levels. No
significant correlation was found (P > 0.05).
No statistically significant difference was found
for the measured arginase activity, NO levels, and
arginine levels in patients with histopathologically
different tumor types (Table 2).
Parameters were evaluated according to different
locations of the tumor; however, no statistically
significant difference was found (P > 0.05).

With the receiver operating characteristic (ROC)
curve of arginase, arginine, and NO, sensitivity and
specificity were calculated. While arginine showed
low accuracy (field: 0.418) (P = 0.144), arginase (field:
0.765) (P < 0.0001) and NO (field: 0.875) (P < 0.0001)
showed high accuracy. Therefore, the sensitivity and
specificity were calculated for these 2 parameters. The
sensitivity and specificity values, as cut-off values, are
shown in Table 3.
Discussion
Many tumor markers such as carcinoembryonic
antigen (CEA), carbohydrate antigen 19-9 (CA
19-9), squamous cell carcinoma (SCC) antigen,
carbohydrate antigen 125 (CA 125), and carbohydrate
antigen 50 (CA 50) have been used in early diagnosis
and for monitoring the response to therapy in
esophageal cancer. In most studies, especially in the
diagnosis of the early stage esophageal cancer, these
tumor markers were found to be of limited use (7).
Arginine significantly decreases in cancer patients
with increasing arginase production, resulting in
a decrease of T-cell proliferation and functional
damage. However, the mechanism of inhibitor
effects on T-cell proliferation in the case of arginine

Table 2. Distribution of the parameters by tumor type.
Parameters

Squamous cell cancer

Arginase activity (U/L)

Adenocarcinoma

P

9.8 ± 7.6

10.4 ± 6.6

P = 0.685

NO level (μmol/L)

15.6 ± 6.1

16.9 ± 3.2

P = 0.457

Arginine level (μmol/L)

43.7 ± 26.7

42.4 ± 28.3

P = 0.184

Table 3. Sensitivity and specificity of arginase and NO based on cut-off values.
Arginase (U/L)
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NO (μmol/L)

Cut-off level

7.2

8.5

10.0

10.4

10.6

11.2

Sensitivity

87%

80%

72%

89%

83%

83%

Specificity

65%

65%

75%

66%

86%

86%
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deficiency remains unclear (8). It has been shown
that arginase activity in tumors induces arginine
deficiency.
It has been shown that ongoing arginase activity in
plasma may cause a decreased arginine concentration
by up to 94% (9). Lamb et al. (10) showed that arginine
deficiency disrupts the DNA synthesis phase of G1.
Hester et al. (11) observed a significant reduction in
tumor mass with arginine administration in mice
with squamous cell carcinomas. Rodriguez et al. (12)
demonstrated that mouse peritoneal macrophages
stimulated with T-helper cytokines produced
arginase; then the arginine concentrations decreased
rapidly and the induction of T-cell dysfunction
occurred.
Naini et al. (13), using age-matched control
groups, found that arginine concentrations were
low in patients with lung cancer but that there was
no change in patients with esophageal cancer. In
the present study, the samples were deproteinized
and age/sex matches were taken into consideration.
Arginine concentrations in patients with esophageal
cancer were significantly lower than those of the
control group (P < 0.0001). New studies are needed
to clarify whether this depends on increased arginine
uptake by the tumor or arginase secretion.
Recent studies have shown that arginase has an
important role in tumor immunobiology. Increased
arginase activity has been reported in different tumor
types. It has been determined that a strong link is
necessary between the proliferation of malignant
cells and their production of arginase. This was
explained by the relationship between the polyamine
production and the support of the malignant cell
proliferation (14).
In past studies, arginase activity was found to
have a close association with various types of cancer,
especially colorectal (15), prostate (16), pancreas (17),
and stomach (18) cancer, where increased arginase
activity has been demonstrated. Chrzanowska et al.
(19), in their study population with hepatocellular
carcinoma, observed that high arginase activity
decreased after resectioning of the tumor. The
relationship between the increased arginase activity
in patients with malignant cells and polyamines has
been considered, and cancer development might
depend on increased polyamine synthesis. Therefore,

it has been noted that arginase might be used as a
biologic marker in the process of cancer development.
Wu et al. (20) investigated serum arginase activity
in patients with peptic ulcer and gastric cancer and
found that serum arginase activity was significantly
higher in gastric cancer patients than in peptic
ulcer patients or healthy individuals. There was no
significant difference between the patients with peptic
ulcer and the control groups. The same researchers
also investigated the relationship between serum
arginase activity and the stage of gastric cancer.
The mean serum arginase activity in patients with
early stage gastric cancer was significantly higher
in the control group. Moreover, serum arginase
activity was higher in the advanced stage of gastric
cancer than in the early-stage gastric cancer and in
the control group. Leu and Wang (15) investigated
serum arginase activity in colorectal cancer patients.
When compared to normal mucosal tissues, arginase
activity was determined to be 2 times higher in the
colorectal cancer tissues.
In a study of lung cancer, arginase activity and the
relationship between the arginase activity and cell
type and extrapulmonary metastasis was examined.
Compared with the healthy control group, all of the
patients with lung cancer, including small cell lung
cancer and nonsmall cell lung cancer and patients
with and without extrapulmonary metastasis, had
significantly higher erythrocyte arginase activities.
On the other hand, between the patients with
nonsmall cell or small cell lung cancer and patients
with or without metastases, no significant difference
in terms of erythrocyte arginase activity was detected
(21). Gökmen et al. (22), in patients with skin cancer,
including basal cell and squamous cell cancer, found
significantly higher ornithine and arginase levels.
However, there was no significant difference in the
levels of ornithine and arginase between squamous
cell carcinoma and basal cell carcinoma. The present
study showed increased arginase activity in patients
with esophageal cancer compared to the healthy
controls (P = 0.005). In addition, arginase sensitivity
and specificity were 87% and 65%, respectively.
This finding supports the data from other studies
conducted with other cancer types, including the
gastrointestinal system. However, no significant
difference in arginase activity according to the distant
407
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organ metastasis and cell type was found.
The carcinogenic effect of NO may arise by
direct DNA and protein damage or the inhibition
of the programmed cell death mechanism. NO
also enhances tumor growth by stimulating tumor
angiogenesis. NO plays a role in several steps of tumor
angiogenesis, such as endothelial cell proliferation,
vascular permeability, and angiogenic growth factor
(23).
In the first report of NO expression of human
tumor cells in 1991, Radomski et al. (24) reported
NO expression in the primary tumor and lymph
node metastases of colorectal adenocarcinoma.
Calcium-independent NOS activity has been shown
in both groups of cells. In the literature, it has been
reported that increased production of nitric oxide
has a critical role in the development of cancer cells
by the stimulation of angiogenesis and increased
mutations via the stimulation of free radicals and
DNA damage (25).
Inducible nitric oxide synthase (iNOS) is an
enzyme that catalyzes the formation of nitric oxide
from arginine. iNOS release and activity results
in high levels of NO production. NO production
at physiological levels is important for mucosal
function and contributes to the protective effects of
gastrointestinal system cells. However, in patients with
chronic inflammatory disease of the gastrointestinal
tract such as ulcerative colitis and gastritis, increased
iNOS release was observed (26).
In a study of breast cancer, a positive relationship
was found between the breast cancer/metastases

and iNOS (27). It has been reported that increased
NO production levels contribute to the formation of
metastasis in breast cancer by increasing angiogenesis.
In the present study, NO levels in patients with
esophageal cancer were found to be significantly
increased compared with the control group (P <
0.0001). In addition, the NO sensitivity and specificity
were calculated as 89% and 66%, respectively. NO
levels in patients with distant metastases were higher
than in patients without metastasis, but there was no
statistical significance (P = 0.31).
Chen et al. (28) demonstrated that iNOS inhibitors
suppress the development of chemically induced
esophageal cancer in rats. This finding suggests
that selective iNOS inhibitors can prevent the
development of esophageal cancer. It is known that
polyunsaturated ω-3 fatty acids, which inhibit NO,
reduce the risk of colon cancer in humans and rats
(29). It has been demonstrated that the inhibition of
NO synthesis in patients with breast cancer decreased
tumor vascularization and thus tumor growth (30).
In conclusion, in the present study, it was found
that plasma arginine, arginase, and nitric oxide levels
in patients with esophageal cancer were significantly
different than those of the control group. This finding
suggests that the arginase enzyme and NO play a
role in the progression of esophageal cancer, and
that arginase activity and NO levels might be used
as markers for the diagnosis of esophageal cancer.
Moreover, arginase and NO blocking agents, with the
support of arginine, can improve esophageal cancer
progression and treatment response. However, more
comprehensive studies are needed.
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